Aurobindo Expects To Be In Top Three For Immunology Biosimilar - Is It Xolair?
Pneumococcal Vaccine Filing In H2
Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar. Scrip examines if it could it be a biosimilar to Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23
